Pieris appoints chief scientific officer

Joins German firm from Merck & Co bringing therapeutic protein drug development expertise

Laurent Audoly has joined Pieris as chief scientific officer. Audoly, most recently Biologics Research Site Lead at Merck & Co, brings both pharma and biotech experience to the German biotechnology company, particularly expertise in therapeutic protein drug development.

‘Laurent’s pharmacology expertise and drug development skills are the precise ingredients we need to maximise the value of our growing therapeutic pipeline,’ saidd Stephen Yoder, chief executive of Pieris.

‘As the company builds and expands its internal and partnered Anticalin pipeline, Laurent's contribution will be significant.’

You may also like

Regulatory

Commercialised anticalin inhaled treatments

Pieris Pharmaceuticals and AstraZeneca collaborate to develop and commercialise treatments for respiratory diseases
Ingredients

Pieris announces first cancer immunotherapy collaboration

Agreement with Roche leverages proprietary Anticalin technology platform
Research & Development

Pieris Pharmaceuticals and the University of Melbourne receive grant

To advance Anticalin-based therapeutic for inhaled delivery to treat asthmatics
Ingredients

Zydus Cadila and Pieris to collaborate on anticalin development

Collaboration combines Pieris’s drug discovery and early development capabilities with Zydus’s expertise in biologics development, regulatory affairs and biologics manufacturing
Research & Development

Scientists develop new technique to fight antimicrobial resistance

The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development

Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures

A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Subscribe now